Abstract: A picture generation unit comprises a light emitter array that is disposed on a substrate and provides a projection imaging light. The light emitter array includes a plurality of light emitting units. Each of the light emitting units includes a plurality of mini LED chips. An electronic control unit is electrically coupled to the substrate to control the mini LED chips to generate the projection imaging light. The light emitter array may emit light as well as present controllable images simultaneously. Because the picture generation unit abandons using the conventional backlight source and the module thereof, it can effectively utilize light energy and reduce radiation heat/waste heat. A vehicular head-up display system using the picture generation unit may improve operation reliability thereof.

Abstract: Data isolators are described. The data isolators include a differential receiver having cross-coupled single-ended amplifiers. The single-ended amplifiers may be referenced to a time-varying reference potential. The cross-coupling of the single-ended amplifiers may provide high speed, low power consumption operation of the data isolator.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: Methods, computer program products, and systems are presented. The method computer program products, and systems can include, for instance: receiving, by a Network Virtualization Edge (NVE) of a first virtual network (VN), a multicast packet from a virtual machine (VM) of the first virtual network (VN); determining, by the NVE, whether the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN), the second virtual network (VN) being logically separated from the first virtual network (VN); responsively to determining that the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN) forwarding, by the NVE, the multicast packet to the second NVE.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): wherein R1-R3 are as defined herein, or pharmaceutically acceptable salts or esters thereof; and a pharmaceutically acceptable carrier.

Abstract: Methods, computer program products, and systems are presented. The methods include, for instance: a gateway stack that includes a master, a backup, and at least one slave amongst nodes of the GS based on an election pursuant to a gateway stack protocol. The gateway stack provides gateway services for a Network Virtualization over Layer 3 (NVO3) network in a fail-safe manner by utilizing all of the nodes in the gateway stack. A data interface between the gateway stack and a switch is aggregated to evenly distribute inbound packets amongst the nodes of the gateway stack.

Abstract: Data isolators are described. The data isolators include a differential receiver having cross-coupled single-ended amplifiers. The single-ended amplifiers may be referenced to a time-varying reference potential. The cross-coupling of the single-ended amplifiers may provide high speed, low power consumption operation of the data isolator.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

Abstract: A method, system, and computer program product for enabling communication between different overlay solutions. The method includes one or more processor obtaining an address resolution request from a first resource in a first domain for a second resource in a second domain. Both domains are in a shared computing environment and the second domain includes a control plane engine. The one or more processor obtains source information from the request, registers the information to the engine, and utilizes the request to query the engine to locate the second resource in the domain. The second resource matches the request. The processor receives a response from the engine identifying a first host and the first host is in the second domain and is the host of the second resource. The processor sends a notification request to the first host requesting that the first host reply to the request.

Abstract: Methods, computer program products, and systems are presented. The method computer program products, and systems can include, for instance: receiving, by a Network Virtualization Edge (NVE) of a first virtual network (VN), a multicast packet from a virtual machine (VM) of the first virtual network (VN); determining, by the NVE, whether the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN), the second virtual network (VN) being logically separated from the first virtual network (VN); responsively to determining that the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN) forwarding, by the NVE, the multicast packet to the second NVE.

Abstract: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

Abstract: Methods of cancer treatment are disclosed. Particularly, disclosed herein are methods of administering LAL and PPAR? ligands for treating various cancer patients to promote anti-cancer immunity (suppress MDSC), use for inhibiting tumor progression, and use for inhibiting tumor metastasis.

Abstract: The present invention provides diagnostics for identifying and distinguishing various types of lung cancers using serum and/or bronchioalveolar lavage fluid. Signatures of secretory proteins are used to identify and distinguish lung cancers. The biomarker signatures may also be used to separate lung cancers from other inflammatory diseases, monitor progression, or assess treatment efficacy.

Abstract: Methods, computer program products, and systems are presented. The methods include, for instance: a gateway stack that includes a master, a backup, and at least one slave amongst nodes of the GS based on an election pursuant to a gateway stack protocol. The gateway stack provides gateway services for a Network Virtualization over Layer 3 (NVO3) network in a fail-safe manner by utilizing all of the nodes in the gateway stack. A data interface between the gateway stack and a switch is aggregated to evenly distribute inbound packets amongst the nodes of the gateway stack.

Abstract: Methods, computer program products, and systems are presented. The methods include, for instance: a gateway stack that includes a master, a backup, and at least one slave amongst nodes of the GS based on an election pursuant to a gateway stack protocol. The gateway stack provides gateway services for a Network Virtualization over Layer 3 (NVO3) network in a fail-safe manner by utilizing all of the nodes in the gateway stack. A data interface between the gateway stack and a switch is aggregated to evenly distribute inbound packets amongst the nodes of the gateway stack.

Abstract: A method, system, and computer program product for enabling communication between different overlay solutions. The method includes one or more processor obtaining an address resolution request from a first resource in a first domain for a second resource in a second domain. Both domains are in a shared computing environment and the second domain includes a control plane engine. The one or more processor obtains source information from the request, registers the information to the engine, and utilizes the request to query the engine to locate the second resource in the domain. The second resource matches the request. The processor receives a response from the engine identifying a first host and the first host is in the second domain and is the host of the second resource. The processor sends a notification request to the first host requesting that the first host reply to the request.

Abstract: A method, system, and computer program product for enabling communication between different overlay solutions. The method includes one or more processor obtaining an address resolution request from a first resource in a first domain for a second resource in a second domain. Both domains are in a shared computing environment and the second domain includes a control plane engine. The one or more processor obtains source information from the request, registers the information to the engine, and utilizes the request to query the engine to locate the second resource in the domain. The second resource matches the request. The processor receives a response from the engine identifying a first host and the first host is in the second domain and is the host of the second resource. The processor sends a notification request to the first host requesting that the first host reply to the request.

Abstract: Methods, computer program products, and systems are presented. The method computer program products, and systems can include, for instance: receiving, by a Network Virtualization Edge (NVE) of a first virtual network (VN), a multicast packet from a virtual machine (VM) of the first virtual network (VN); determining, by the NVE, whether the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN), the second virtual network (VN) being logically separated from the first virtual network (VN); responsively to determining that the NVE currently supports forwarding the multicast packet to a second NVE of a second virtual network (VN) forwarding, by the NVE, the multicast packet to the second NVE.

Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.